3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with Myoclonic Jerk in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beukers, RJ; Booij, J; Tijssen, MA; van Amelsvoort, TA; Weisscher, N; Zijlstra, F | 1 |
| Emrich, D; Hajak, G; Kögler, A; Munz, DL; Riemann, H; Rüther, E; Staedt, J; Stoppe, G | 1 |
1 trial(s) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Myoclonic Jerk
| Article | Year |
|---|---|
Single photon emission tomography (SPET) imaging of dopamine D2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome (NMS).
Topics: Aged; Benzamides; Brain; Brain Chemistry; Bromocriptine; Dopamine; Dopamine Agents; Dopamine Agonists; Dopamine Antagonists; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Middle Aged; Myoclonus; Polysomnography; Pyrrolidines; Receptors, Dopamine D2; Sleep Wake Disorders; Tomography, Emission-Computed, Single-Photon | 1995 |
1 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Myoclonic Jerk
| Article | Year |
|---|---|
Reduced striatal D2 receptor binding in myoclonus-dystonia.
Topics: Adult; Aged; Benzamides; Case-Control Studies; Dystonia; Female; Humans; Male; Middle Aged; Mutation; Myoclonus; Neostriatum; Occipital Lobe; Protein Binding; Pyrrolidines; Receptors, Dopamine D2; Tomography, Emission-Computed, Single-Photon | 2009 |